Adaptimmune ADAP Stock News

Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) is running for the top in the market today after reporting positive clinical data in a press release this morning. In other news, the company announced a new hire and a change to its R&D leadership. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

ADAP Stock Rockets On Positive Data

As mentioned above, Adaptimmune Therapeutics issued a press release early this morning announcing the positive results. The results were reported at the 38th JP Morgan Healthcare Conference, ultimately showing strong efficacy and safety across the company’s SPEAR T-cell platform in patients with various forms of solid tumors.

In the release, ADAP outlined data from four key patients across multiple clinical trials. The first patient is fighting with hepatocellular carcinoma, also known as liver cancer. After being treated int he third cohort of the Phase 1 ADP-A2AFP clinical trial, the patient showed a confirmed partial response with a decrease of 100% in target lesions.

The second patient is fighting metastatic rectal mucosal melanoma. This patient was the first patient treated in the low-dose radiation sub-study of the Phase 1 ADP-A2M4 clinical trial. After being treated, the patient achieved a confirmed partial response with a decrease of 42% in target lesions.

The fourth patient was treated in the first cohort of the next-generation SURPASS clinical trial. After being treated to address metastatic gastro-esophageal junction cancer, this patient achieved an unconfirmed partial response with a decrease of 42% in target lesions.

Finally, ADAP pointed to a patient with head and neck cancer that was treated as part of the expansion phase of the Phase 1 ADP-A2M4 clinical trial. This patient achieved an unconfirmed partial response with a 36% reduction in target lesions.

In the release, Adaptimmune said that there continues to be a favorable risk:benefit profile on all products and indications under study. In fact, the most common adverse events are the types of events that patients expect to experience when undergoing cytotoxic chemotherapy and other cancer immunotherapies.

In a statement, Adrian Rawcliffe, CEO at ADAP, had the following to offer:

These responses demonstrate that our proprietary SPEAR T-cell platform is clearly active and can overcome the challenges of treating a range of solid tumors with a T-cell therapy product. These are early results and we need more patient data and durability information to determine which therapies to develop. Nonetheless, this is a critical demonstration of the value of our SPEAR T-cell therapies for people with cancer and a validation of the importance of our proprietary affinity engineering. I couldn’t be prouder of the team at Adaptimmune, and we are grateful to the investigators and patients who have put their faith in our treatment. We look forward to presenting data from these trials at future scientific congresses.

In Other News

In other news, ADAP announced that it is making major changes to its R&D organization. In particular, the company has hired Dr. Elliot Norry as SVP and CMO effective immediately.

In a statement, Adrian Rawcliffe, CEO at ADAP, had the following to offer:

Elliot has done a fantastic job as acting CMO over the past few months. This builds on his impact leading the ADP-A2AFP program in liver cancer as well as leading our safety and pharmacovigilance team over the last four years. I look forward to continuing to work with Elliot to deliver cell therapy treatments to patients with cancer. In addition, we have made changes to our R&D leadership to accelerate how our products move from research to late stage development, including rapid application of translational learnings that are crucial to bringing cell therapies to patients.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.